

Form PTO-1594

RF

U.S. DEPARTMENT OF COMMERCE

(Rev. 10/02) 1023 OMB No. 0651-0027 (exp. 6/30/2005)	U.S. Patent and Trademark Office
Tab settings ⇔⇔ ♥ ▼	* * * *
To the Honorable Commissioner of Patents and Trademarks:	Please record the attached original documents or copy thereof.
1. Name of conveying party(ies): WIT IP Corporation 136 Turnpike Road Southborough, MA 01772 ☐ Individual(s) ☐ Association ☐ General Partnership ☐ Limited Partnership ☐ Corporation-State ☐ Other Additional name(s) of conveying party(ies) attached? ☐ Yes ☐ No 3. Nature of conveyance: ☐ Assignment ☐ Merger ☐ Security Agreement ☐ Change of Name ☐ Other Supplement	2. Name and address of receiving party(ies) Name: JPMorgan Chase Bank, as Administrative Agent Internal Address: Street Address: 270 Park Avenue City: New York State: NY Zip: 10017 Individual(s) citizenship Association General Partnership Limited Partnership Corporation-State New York Other If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No
Execution Date: December 3, 2002	(Designations must be a separate document from assignment) Additional name(s) & address(es) attached? Yes No
4. Application number(s) or registration number(s): A. Trademark Application No.(s) Please see attached schedule Additional number(s) attached.	B. Trademark Registration No.(s) Please see attached schedule tached Yes No
Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and registrations involved:
Name: Ms. Penelope Agadoa Internal Address: Federal Research Corporation	7. Total fee (37 CFR 3.41)
Street Address: 1030 Fifteenth St. NW, Suite 920	8. Deposit account number:
City: Washington State: DC Zip: 20005	(Attach duplicate copy of this page if paying by deposit account)
9. Statement and signature.	INIS SPACE
To the best of my knowledge and belief, the foregoing inform copy of the original document.	nation is the and correct and any attached copy is a true
David J. Miller	December 10, 2002
	gnature Date principles and document:

12/12/2002 LMUELLER 00000072 75603169

documents to be recorded with required cover sheet information to:

Commissioner of Patent & Trademarks, Box Assignments Washington, D.C. 20231

01 FC:8521

40.00 DP 100.00 DP

United States THERMOFLEX United States THERMOPLASTY United States THERMOPLASTY United States THERMOPLASTY United States THERMOPLASTY Argomed, Inc., Delaware Corp. United States THERMOPLASTY Argomed, Inc., New Jersey Co New Jersey Co New Jersey Co New Jersey Co Seuropean THERMOFLEX Israeli Corp. Israeli Corp.			Registrant/Annlicant	Filing Date	Registration	Serial	Registration
ttes ARGOMED and Design ttes Flame Design ttes THERMOFLEX ttes PROSTAPLASTY ttes THERMOPLASTY THERMOPLASTY							Number
ttes Flame Design ttes THERMOFLEX ttes PROSTAPLASTY ttes THERMOPLASTY THERMOPLEX	1	MED and Design	Argomed, Inc.	December 10, 1998	November 27, 2001	75/603,169	2,513,070
ttes Flame Design ttes THERMOFLEX ttes PROSTAPLASTY ttes THERMOPLASTY THERMOPLEX			New Jersey Corp.				
ites THERMOFLEX Ites PROSTAPLASTY Ites THERMOPLASTY THERMOFLEX	_	Design	Argomed, Inc.	January 12, 1999	November 27, 2001	75/619,636	2,513,079
ites THERMOFLEX Ites PROSTAPLASTY Ites THERMOPLASTY THERMOFLEX			New Jersey Corp.				
ites PROSTAPLASTY Ites THERMOPLASTY THERMOFLEX	\downarrow	MOFLEX	Argomed Ltd.,	January 7, 1997	February 3, 1998	75/223,270	2,134,195
ites PROSTAPLASTY ITHERMOPLASTY THERMOFLEX							
Ites THERMOPLASTY THERMOFLEX		APLASTY		December 10, 1998	N/A	75/604,101	N/A
Ites THERMOPLASTY THERMOFLEX		; 	Delaware Corp.				
THERMOFLEX	\downarrow	MOPLASTY	Argomed, Inc.,	March 11, 2000	Abandoned	/5/941,995	Арапоопео
THERMOFLEX			New Jersey Corp				
		MOFLEX	Argomed Ltd.,	April 1, 1996	May 5, 1998	000107656	000101000
	munity		Israeli Corp.				

Supplement No. 1 to Security Agreement

WIT IP CORPORATION

SUPPLEMENT NO. 1 dated as of December 3, 2002, to the Security Agreement dated as of November 12, 1999, among ACMI CORPORATION (f/k/a Circon Corporation), a Delaware corporation (the "Borrower"), AMERICAN CYSTOSCOPE MAKERS, INC. (f/k/a Circon Holdings Corporation), a Delaware corporation ("Holdings"), each subsidiary of the Borrower listed on Schedule I thereto (each such subsidiary individually a "Subsidiary Guarantor" and, collectively, the "Subsidiary Guarantors"; the Subsidiary Guarantors, Holdings and the Borrower are referred to collectively herein as the "Grantors") and JPMORGAN CHASE BANK (f/k/a The Chase Manhattan Bank), a New York banking corporation ("Chase"), as collateral agent (in such capacity, the "Collateral Agent") for the Secured Parties (as defined herein).

- A. Reference is made to (a) the Credit Agreement dated as of November 12, 1999 (as amended, supplemented or otherwise modified from time to time, the "Credit Agreement"), among the Borrower, Holdings, the lenders from time to time party thereto (the "Lenders"), Chase, as administrative agent for the Lenders (in such capacity, the "Administrative Agent"), Collateral Agent, swingline lender and issuing bank (in such capacity, the "Issuing Bank"), Bankers Trust Company, as co-documentation agent for the Lenders, Merrill Lynch Capital Corporation, as co-documentation agent for the Lenders, Canadian Imperial Bank of Commerce, as co-syndication agent for the Lenders, and Credit Suisse First Boston, as co-syndication agent for the Lenders, (b) the Parent Guarantee Agreement dated as of November 12, 1999 (as amended, supplemented or otherwise modified from time to time, the "Parent Guarantee Agreement"), between Holdings and the Collateral Agent and (c) the Subsidiary Guarantee Agreement dated as of November 12, 1999 (as amended, supplemented or otherwise modified from time to time, the "Subsidiary Guarantee Agreement"), among the Subsidiary Guarantors and the Collateral Agent.
- B. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Security Agreement and the Credit Agreement.
- C. The Grantors have entered into the Security Agreement in order to induce the Lenders to make Loans and the Issuing Bank to issue Letters of Credit. Section 6.15 of the Security Agreement provides that additional Subsidiaries of the Borrower may become Grantors under the Security Agreement by execution and delivery of an instrument in the form of this Supplement. The undersigned Subsidiary (the "New Grantor") is executing this Supplement in accordance with the requirements of the Credit Agreement to become a Grantor under the Security Agreement in order to induce the Lenders to make additional Loans and the Issuing Bank to issue additional Letters of Credit and as consideration for Loans previously made and Letters of Credit previously issued.

Accordingly, the Collateral Agent and the New Grantor agree as follows:

SECTION 1. In accordance with Section 6.15 of the Security Agreement, the New Grantor by its signature below becomes a Grantor under the Security Agreement with the same force and effect as if originally named therein as a Grantor and the New Grantor hereby (a) agrees to all the terms and provisions of the Security Agreement applicable to it as a Grantor thereunder and (b) represents and warrants that the representations and warranties made by it as a Grantor thereunder are true and correct on and as of the date hereof. In furtherance of the foregoing, the New Grantor, as security for the payment and performance in full of the Obligations (as defined in the Security Agreement), does hereby create and grant to the Collateral Agent, its successors and assigns, for the benefit of the Secured Parties, their successors and assigns, a security interest in and lien on all of the New Grantor's right, title and interest in and to the Collateral (as defined in the Security Agreement) of the New Grantor.

<<NYCORP~2205116.2:4417B:12/03/02-12:56p>>

Each reference to a "Grantor" in the Security Agreement shall be deemed to include the New Grantor. The Security Agreement is hereby incorporated herein by reference.

- SECTION 2. The New Grantor represents and warrants to the Collateral Agent and the other Secured Parties that this Supplement has been duly authorized, executed and delivered by it and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms.
- SECTION 3. This Supplement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Supplement shall become effective when the Collateral Agent shall have received counterparts of this Supplement that, when taken together, bear the signatures of the New Grantor and the Collateral Agent. Delivery of an executed signature page to this Supplement by facsimile transmission shall be as effective as delivery of a manually signed counterpart of this Supplement.
- SECTION 4. The New Grantor hereby represents and warrants that (a) set forth on Schedule I attached hereto is a true and correct schedule of the location of any and all Collateral of the New Grantor and (b) set forth under its signature hereto, is the true and correct location of the chief executive office of the New Grantor.
- SECTION 5. Except as expressly supplemented hereby, the Security Agreement shall remain in full force and effect.
- SECTION 6. THIS SUPPLEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.
- SECTION 7. In case any one or more of the provisions contained in this Supplement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and in the Security Agreement shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction). The parties hereto shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.
- SECTION 8. All communications and notices hereunder shall be in writing and given as provided in Section 6.01 of the Security Agreement. All communications and notices hereunder to the New Grantor shall be given to it at the address set forth under its signature below.
- SECTION 9. The New Grantor agrees to reimburse the Collateral Agent for its reasonable out-of-pocket expenses in connection with this Supplement, including the reasonable fees, other charges and disbursements of counsel for the Collateral Agent.

<<NYCORP-2205116.2:4417B:12/03/02-12:56p>>

IN WITNESS WHEREOF, the New Grantor and the Collateral Agent have duly executed this Supplement to the Security Agreement as of the day and year first above written.

Name	Of New Grantor,
by	
-	Name:
	Title:
	Address:
	Organizational ID:
JPMO	RGAN CHASE BANK (f/k/a The Chase
	attan Bank), as Collateral Agent,
by	Olun Olu Olum_
•	Name: Title: DAWN LEE LUM VICE PRESIDENT

IN WITNESS WHEREOF, the New Grantor and the Collateral Agent have duly executed this Supplement to the Security Agreement as of the day and year first above written.

WIT IP CORPORATION
Name Of New Grantor,
by Name: Date J. Aere Title: Troas you Address: 136 Temple Reed Sathleragh, WH Organizational ID: Debugne ID: 000600334_01772 EIW! 06-1660319 IPMORGAN CHASE BANK (f/k/a The Chase
Address: (36 TWAPIUP KEED Salakaagh Wiff
EIN'. 06-1660319 10. 030600334 01772
JPMORGAN CHASE BANK (f/k/a The Chase Manhattan Bank), as Collateral Agent,
by
Name:
Title:

SCHEDULE I to Supplement No. 1 to the Security Agreement

LOCATION OF COLLATERAL

Description

Intellectual Property and other interlogibles (and see attached Schedules) and all tangiole assets located in the U.S.

Location

136 Tumple Road Sorthbowagh, MH 01772

<<NYCORP-2205116,2:4417B:12/03/02-12:56p>>

Patents

United States	United States			United States		United States			United States	United States		United States				United States	-	United States				United States	United States	United States	United States	United States	United States	United States		United States		Country
COMBINATION TREATMENT CATHETERS AND POST- TREATMENT STENTS	TREATMENT CATHETERS WITH THERMALLY INSULATED REGIONS	URETHRA USING BIODEGRADABLE STENTS	INHIBITING OBSTRUCTION OF THE PROSTATIC	METHODS FOR TREATING THE PROSTATE AND	IN VIVO	CATHETERS WITH SUCTION CAPABILITY AND KELATED	TREATMENT PRESSURES AND RELATED METHODS	TISSUE PENETRATION DEPTH USING ADJUSTABLE	THERMAL TREATMENT SYSTEMS WITH ENHANCED	METHODS FOR TREATING PROSTATITIS	MEDICAL DEVICE BALLOONS	LOW THERMAL RESISTANCE ELASTIC SLEEVES FOR	URETHRA	INHIBITING OBSTRUCTION OF THE PROSTATIC	ENGAGING ANCHORING MEANS AND METHODS FOR	PROSTATIC STENT WITH LOCALIZED TISSUE	INSULATED REGIONS	TREATMENT CATHETERS WITH THERMALLY	URETHRA	INHIBITING OBSTRUCTION OF THE PROSTATIC	ENGAGING ANCHORING MEANS AND METHODS FOR	PROSTATIC STENT WITH LOCALIZED TISSUE	THERMAL TREATMENT APPARATUS	THERMAL TREATMENT APPARATUS	INTERNAL CATHETER	INTERNAL CATHETER	THERMAL TREATMENT APPARATUS	THERMAL TREATMENT APPARATUS	OF MAMMALS	TECHNIQUE FOR LOCALIZED THERMAL TREATMENT		Title
December 10, 2001	November 13, 2001	12 2001		November 13, 2001		October 17, 2001	2 17 2001		September 10, 2001	July 27, 2001		May 1, 2001				April 18, 2001		November 13, 2000				June 30, 2000	March 28, 2000	November 5, 1999	January 29, 1999	February 4, 1998	April 16, 1996	March 11, 1994		March 14, 1991		Filing Date
NA	N/A	71/2		N/A		N/A	NI/A		N/A	N/A		N/A				N/A		N/A				N/A	May 14, 2002	1	N/A	June 29, 1999	N/A	August 27, 1990	2001	November 2, 1993		Issue Date
00/337,327	10/011,/00	10/011 700		10/011,494		00,000,020	000 011/03		60/318,556	60/308,344		60/288,774	00000			09/63/,460	20177 400	60/248,109	20.20100			00/215,100	09/334,842	09/453,932	09/23,512	09/010,004	06/032,630	00/627 920	00/212 107	07/669,366	Number	Application
TOO	N/A	N/A	-	N/A	77/4	,	N/A		N/A	N/A	31/4	N/A	N1/A			Z/N	71/7	N/A	71/4			N/A	KE3/,/04	N/A	N/A	3,910,175	5016105	NI/A	055 005 5	5,257,977	Number	Patent

Country	Title	Filing Date	Issue Date	Application Number	Patent Number
Tinited States	MODILI AR THERMAL TREATMENT SYSTEMS WITH	December 20, 2001	N/A	60/342,566	N/A
Office States	SINGLE-USE DISPOSABLE CATHETER ASSEMBLIES AND				
	RELATED METHODS			202 20101	z
United States	LOW THERMAL RESISTANCE ELASTIC SLEEVES FOR	May 1, 2002	N/A	10/150,005	145
	MEDICAL DEVICE BALLOONS			CO/201 C/7	Z
United States	METHODS FOR TREATING PROSTATITIS	May 17, 2002	N/A	11, 62, 52	<u> </u>
Australia	PROSTATIC STENT WITH LOCALIZED TISSUE	May 15, 2001	January 14, 2002	AU 03122	WO 700107177
	ENGAGING ANCHORING MEANS AND METHODS FOR				
	INHIBITING OBSTRUCTION OF THE PROSTATIC				
	URETHRA		10000	N/A	AT 131007
Austria	APPARATUS FOR LOCALIZED THERMAL TREATMENT	N/A	December 15, 1995	N/A	,
	OF MAMMALS		1006	ΠK	DK 449472T
Denmark	APPARATUS FOR LOCALIZED THERMAL TREATMENT	March 18, 1991	April 22, 1990	19950913022T	 !
	OF MAMMALS	1000	October 2 1001	EP 91307795 0	FP449472 A
European	A TECHNIQUE FOR LOCALIZED THERMAL TREATMENT	March 18, 1991	October 2, 1771	11	ļ
Community	OF MAMMALS	March 18 1001	December 6, 1995	EP 91302295.0	EP449472 B
European	A TECHNIQUE FOR LOCALIZED I HERMAL I REALMENT	INIGICAL TO, 1991		,	
Community	OF MAMMALS	March 6 1005	N/A	EP 95103189.7	N/N
European	THERMAL TREATMENT APPARATUS	March o, 1775	7	3	
Community	THERMAI TREATMENT APPARATIS	April 16, 1997	October 22, 1997	EP 97106282.3	EP 0801938
Community					
European	URETHRAL CATHETER AND GUIDE	February 4, 1999	August 18, 1999	EP 101640	EP 9539//
Community		16 1001	Tanaar: 19 1006	DE 615096	EP 302295 A
Germany	A TECHNIQUE FOR LOCALIZED THERMAL TREATMENT	March 18, 1991	January 10, 1770	70000	ļ
	OF MAMMALS		21 1006	11 038/7	11 03847
Israel	APPARATUS FOR LOCALIZED THERMAL TREATMENT	March 22, 1990	October 31, 1993	TT 22047	Ē
	OF MAMMALS		2001	723061 11	170674
Israel	THERMAL TREATMENT APPARATUS	April 15, 1997	March 19, 2001	IL 1200/4	1 5
Ishan	APPARATIS FOR LOCALIZED THERMAL TREATMENT	March 22, 1991	April 8, 2002	JP 132333	JP 3272373
- appar	OF MAMMAIS				
Innon	THERMAI TREATMENT APPARATUS	March 10, 1995	November 30, 2001	JP 779578	JP 3255820
Japan	THE MAI TOP ATMENT APPARATIS	April 16, 1997	February 10, 1998	JP 98992	JP 10033582
Јарап	TIDENTAL INCATERED AND CHIDE	January 28, 1999	November 24, 1999	JP 20563	JP 11319074
Japan	URE HRAL CALIBETEN AND COME	,			

atents

Country	Title	Filing Date	Issue Date	Application Number	Patent Number
PCT	PROSTATIC STENT WITH LOCALIZED TISSUE	May 15, 2001	January 10, 2001	PCT/US01/15585	WO 02/02032
,	ENGAGING ANCHORING MEANS AND METHODS FOR				
	INHIBITING OBSTRUCTION OF THE PROSTATIC				
	URETHRA		27)		N/A
PCT	HYPERTHERMY TREATMENT OF THE PROSTATE AND	November 13, 2001	N/A	rC1/0301/4//02	145
	IMPLANTATION OF THE BIODEGRADABLE URETHRAL				
	STENT				N/A
PCT	TREATMENT CATHETERS WITH THERMALLY	November 13, 2001	N/A	FC1/0301/4//33	14/5
	INSULATED REGIONS				71/A
PCT	LOW THERMAL RESISTANCE ELASTIC SLEEVES FOR	May 2, 2002	N/A	FC1/0002/10000	
	MEDICAL DEVICE BALLOONS			ורכו ביים יים יים יים	N1/A
PCT	METHODS FOR TREATING PROSTATITIS	July 24, 2002	N/A	-	14/2
PCT	CATHETERS WITH SUCTION CAPABILITY AND RELATED	September 25, 2002	N/A	PC1/0302/3334	12/2
	METHODS AND SYSTEMS FOR OBTAINING BIOSAMPLES				
	IN VIVO		X1/1	8898C/CUSI I/JUG	N/A
PCT	THERMAL TREATMENT SYSTEMS WITH ENHANCED	September 9, 2002	N/A	FC1/0002/20060	14/2
	TISSUE PENETRATION DEPTH USING ADJUSTABLE				
	TREATMENT PRESSURES AND RELATED METHODS			בח המחומ מים	T CC2580C 33
Spain	A TECHNIQUE FOR LOCALIZED THERMAL TREATMENT	March 18, 1991	April 16, 1996	EP 302293	E9 2003322 13
•	OF MAMMALS				

					2	
Country	Mark	Registrant/Applicant Filing Date	Filing Date	Registration	Serial	Kegisti auou
Comment	100				Number	Number
I inited States	ARGOMED and Design	Argomed, Inc.	December 10, 1998	November 27, 2001	75/603,169	2,513,070
	•	New Jersey Com				
		New Jersey Corp.			2010101	2 613 070
United States	Flame Design	Argomed, Inc.	January 12, 1999	November 27, 2001	/3/619,636	2,313,079
		New Jersey Corp.				
United States	THERMOFLEX	Argomed Ltd.,	January 7, 1997	February 3, 1998	75/223,270	2,134,195
		Israeli Corp.				
United States	PROSTAPLASTY	Argomed, Inc.,	December 10, 1998 N/A	N/A	75/604,101	NA
		Delaware Corp.				
United States	THERMOPLASTY	Argomed, Inc.,	March 11, 2000	Abandoned	75/941,995	Abandoned
		New Jersey Corp				
European	THERMOFLEX	Argomed Ltd.,	April 1, 1996	May 5, 1998	000107656	9C9/01000
Community		Israeli Corp.				

TRADEMARK REEL: 002630 FRAME: 0921 **RECORDED: 12/11/2002**